Which federal agency does National Community Pharmacists Association comment on most?

National Community Pharmacists Association is most active at the Food and Drug Administration.

National Community Pharmacists Association

Unclaimed

Website

Engagement overview

National Community Pharmacists Association has filed 165 public comments across 137 dockets at 8 federal agencies, most actively at the Food and Drug Administration.

National Community Pharmacists Association

Engagement overview

Is this your organization?

Agency footprint

Dockets (137)

Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure

DOJ and FTC Seek Public Comment for Guidance on Business Collaborations

Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products

Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information

Increasing Availability of Nonprescription Drugs; Request for Information

Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment under the Drug Supply Chain Security Act

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women

Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs from Bulk Drug Substances

ACIP - Committee Meeting (June 25-26, 2025)

Enhancing Coverage of Preventive Services under the Affordable Care Act

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List

Listening Session: Optimizing FDA’s Use of and Processes for Advisory Committees; Public Meeting; Request for Comments

Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

Medication Guides: Patient Medication Information; Proposed Rule

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act

Request for Information; Coverage of Over-the-Counter Preventive Services

Development of Small Dispensers Assessment under the Drug Supply Chain Security Act; Request for Comments

Draft Merger Guidelines for Public Comment

Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

In-Home Safe Disposal Systems; Request for Information

Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; Request for Comments

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

FTC Seek Comments on Trade Regulation Rule on Commercial Surveillance and Data Security, R111004

Proposal to Withdraw Marketing Approval; Notice of Opportunity for a Hearing

DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information; Availability

Identifying Trading Partners Under the Drug Supply Chain Security Act

Advisory Committee on Immunization Practices (ACIP); Notice of Meeting and Request for Comment

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Solicitation for Public Comments on the Impact of Prescription Benefit Managers’ Business Practices

Request for Information on Merger Enforcement

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act

Request for Public Comment Regarding Contract Terms That May Harm Fair Competition

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments

Compounding Animal Drugs from Bulk Drug Substances; Draft Guidance for Industry; Availability

Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information.

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act

Secure Electronic Prior Authorization for Part D Drugs CMS-4189-P

Request for Information: Reducing Administrative Burden to put Patients over Paperwork (CMS-6082-NC)

Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability

Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products Between the States and the Food and Drug Administration; Revised Draft; Availability

Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments

Nonproprietary Naming of Biological Products

Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Medicaid and Children’s Health Insurance Plan (CHIP) Managed Care (CMS-2408-P)

Future Format of the National Drug Code; Public Hearing; Request for Comments

Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, and Medicaid Managed Care Programs for Contract Year 2020 CMS-4185-P

Regulation to Require Drug Pricing Transparency CMS-4187-P

Insanitary Conditions at Compounding Facilities

Innovative Approaches for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Opioid Policy Steering Committee prescribing intervention – exploring a strategy for implementation; Public Hearing; Request for Comments

Review of Existing Center for Drug Evaluation and Research Regulatory and Information Collection Requirements

Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs For Contract Year 2019 CMS-4182-P

Opioid Policy Steering Committee

Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019 (CMS-9930-P)

Administering the Hatch-Waxman Amendments: Ensuring an Appropriate Balance Between Innovation and Access

Training for Opioid Analgesic Prescribers--Exploring the Path Forward

Evaluation of Existing Regulations

Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers; Draft Guidance for Industry; Availability

List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability